Anti-MCP3 antibody [EPR22649-155]
- RabMAb
- Recombinant
- KO Validated
- What is this?
Be the first to review this product! Submit a review
|
(7 Publications)
Rabbit Recombinant Monoclonal MCP3 antibody. Suitable for IP, WB and reacts with Mouse, Human, Transfected cell lysate - Mouse samples. Cited in 7 publications.
View Alternative Names
MCP3, SCYA6, SCYA7, CCL7, C-C motif chemokine 7, Monocyte chemoattractant protein 3, Monocyte chemotactic protein 3, NC28, Small-inducible cytokine A7, MCP-3
- IP
Unknown
Immunoprecipitation - Anti-MCP3 antibody [EPR22649-155] (AB228979)
MCP3 was immunoprecipitated from 0.35 mg RAW264.7 (mouse Abelson murine leukemia virus-induced tumor macrophage) (treated with 80 nM Phorbol-12-myristate-13-acetate (PMA) for 24 hours, then with 100 ng/ml lipopolysaccharides (LPS) treated for 6 hours with addition of 1ug/ml of Brefeldin A for the last 3 hours), whole cell lysate with ab228979 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab228979 at 1/500 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366) was used at 1/1000 dilution.
Lane 1 : RAW264.7 (treated as above) whole cell lysate 10ug
Lane 2 : ab228979 IP in RAW264.7 (treated as above) whole cell lysate.
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab228979 in RAW264.7 (treated as above) whole cell lysate.
Blocking and dilution buffer and concentration : 5% NFDM/TBST.
Exposure time : 3 min.
All lanes:
Immunoprecipitation - Anti-MCP3 antibody [EPR22649-155] (ab228979)
Predicted band size: 11 kDa
false
- WB
Lab
Western blot - Anti-MCP3 antibody [EPR22649-155] (AB228979)
Lanes 1 - 6 : Merged signal (red and green). Green - ab228979 observed at 14 kDa. Red - loading control ab8245 (Mouse anti-GAPDH antibody [6C5]) observed at 37 kDa.
ab228979 was shown to react with MCP3 in RAW 264.7 wild-type cells in Western blot with loss of signal observed in CCL7 knockout sample. Wild-type and CCL7 knockout RAW 264.7 cell lysates were subjected to SDS-PAGE. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with ab228979 and ab8245 (Mouse anti-GAPDH antibody [6C5]) overnight at 4 °C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 h at room temperature before imaging.
All lanes:
Western blot - Anti-MCP3 antibody [EPR22649-155] (ab228979) at 1/1000 dilution
Lane 1:
Wild-type RAW 264.7 untreated control cell lysate at 30 µg
Lane 2:
Wild-type RAW 264.7 PMA treated (80 nM, 24 h) plus LPS treated (100 ng/ml, 6 h) and Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>) treated (5 µg/ml, 5 h) cell lysate at 30 µg
Lane 2:
Western blot - Mouse CCL7 knockout RAW 264.7 cell line (<a href='/en-us/products/cell-lines/mouse-ccl7-knockout-raw-2647-cell-line-ab273755'>ab273755</a>)
Lane 3:
CCL7/MCP3 knockout RAW 264.7 untreated cell lysate at 30 µg
Lane 4:
CCL7/MCP3 knockout RAW 264.7 PMA treated (80 nM, 24 h) plus LPS treated (100 ng/ml, 6 h) and Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>) treated (5 µg/ml, 5 h) cell lysate at 30 µg
Lane 5:
J774A.1 Glucose treated (138.8 mMol/L, 8 h) plus Brefeldin A treated (5 µg/ml, 6 h) and Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>) treated (5 µg/ml, 5 h) cell lysate at 30 µg
Lane 6:
J774A.1 Glucose treated (5.6 mMol/L, 8 h) plus Brefeldin A treated (5 µg/ml, 6 h) and Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>) treated (5 µg/ml, 5 h) cell lysate at 30 µg
Predicted band size: 11 kDa
Observed band size: 14 kDa
false
- WB
Lab
Western blot - Anti-MCP3 antibody [EPR22649-155] (AB228979)
Blocking and diluting buffer and concentration : 5% NFDM/TBST.
Exposure time : 3 minutes.
All lanes:
Western blot - Anti-MCP3 antibody [EPR22649-155] (ab228979) at 1/1000 dilution
Lane 1:
Untreated RAW264.7 (mouse Abelson murine leukemia virus-induced tumor macrophage), whole cell lysate at 40 µg
Lane 2:
RAW264.7 (treated with 80 nM Phorbol-12-myristate-13-acetate (PMA) for 24 hours, then with 100 ng/ml lipopolysaccharides (LPS) treated for 6 hours with addition of 1ug/ml of Brefeldin A for the last 3 hours), whole cell lysate 40 ug.
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 11 kDa
Observed band size: 11 kDa
false
- WB
Lab
Western blot - Anti-MCP3 antibody [EPR22649-155] (AB228979)
Blocking and diluting buffer and concentration : 5% NFDM/TBST.
Exposure time : 10 seconds.
All lanes:
Western blot - Anti-MCP3 antibody [EPR22649-155] (ab228979) at 1/1000 dilution
Lane 1:
HEK-293T (human embryonic kidney) transfected with an empty vector (vector control), containing a myc-His-tag®, whole cell lysate at 20 µg
Lane 2:
HEK-293T transfected with MCP3 expression vector containing a myc-His-tag®, whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 11 kDa
Observed band size: 16-25 kDa
false
Related conjugates and formulations (1)
-
Anti-MCP3 antibody [EPR22649-155] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
MCP-3 interacts with several chemokine receptors such as CCR1 CCR2 and CCR3 allowing for diverse roles in immune response and inflammation. It functions as both a monomer and in conjunction with other chemokines to form heterodimers aiding in the modulation and fine-tuning of the immune response. The presence of MCP-3 in inflammatory tissues indicates its contribution to directing leukocyte migration and positioning therefore supporting both innate and adaptive immunity.
Pathways
MCP-3 is a component of the chemokine signaling pathway and is significant in the regulation of immune surveillance. It interacts closely with proteins such as CCL2 and CCL3 all of which bind to similar receptors like CCR2 and CCR5. MCP-3's involvement in these pathways supports cellular responses to inflammation and infection and its activity has a direct impact on the mobilization and activation of immune cells.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (7)
Recent publications for all applications. Explore the full list and refine your search
Nature communications 16:6794 PubMed40701970
2025
Applications
Unspecified application
Species
Unspecified reactive species
iScience 28:112177 PubMed40224025
2025
Applications
Unspecified application
Species
Unspecified reactive species
Materials today. Bio 31:101511 PubMed39925717
2025
Applications
Unspecified application
Species
Unspecified reactive species
Environmental toxicology 38:1743-1755 PubMed37021908
2023
Applications
Unspecified application
Species
Unspecified reactive species
Oncology letters 24:307 PubMed35949606
2022
Applications
Unspecified application
Species
Unspecified reactive species
Small methods 6:e2100752 PubMed35023642
2022
Applications
Unspecified application
Species
Unspecified reactive species
iScience 24:102700 PubMed34235408
2021
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com